- Home
- TENX vs IMA Comparison
TENX vs IMA Comparison
Compare TENX & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TENX | IMA |
|---|---|---|
| Founded | 1967 | 2019 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.2M | 65.3M |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | TENX | IMA |
|---|---|---|
| Price | $15.20 | $4.85 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $29.67 | $16.00 |
| AVG Volume (30 Days) | ★ 386.9K | 22.3K |
| Earning Date | 03-10-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.64 | $5.35 |
| 52 Week High | $18.38 | $17.50 |
Technical Indicators
Market Signals| Indicator | TENX | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 59.84 | 28.40 |
| Support Level | $11.29 | N/A |
| Resistance Level | $16.27 | $7.28 |
| Average True Range (ATR) | 1.25 | 0.46 |
| MACD | 0.10 | -0.06 |
| Stochastic Oscillator | 70.39 | 41.72 |
Price Performance
Historical ComparisonAbout TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.